Scott Weaner, DO
Neurology · Mercerville, NJNPI 1922084219
Payments from drug & device makers
Across 248 payments — averaging $27.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Biogen$796
- Teva Pharmaceuticals USA, Inc.$633
- Amgen$523
- E.r. Squibb & Sons, L.L.C.$448
- Axsome Therapeutics, Inc.$373
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,65498%
- Education$1032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $1,469 |
| Biogen | 27 | $796 |
| Teva Pharmaceuticals USA, Inc. | 31 | $633 |
| Amgen | 7 | $523 |
| E.r. Squibb & Sons, L.L.C. | 4 | $448 |
| Axsome Therapeutics, Inc. | 5 | $373 |
| UCB, Inc. | 18 | $369 |
| Lilly USA, LLC | 10 | $251 |
| Avanir Pharmaceuticals, Inc. | 13 | $249 |
| AstraZeneca | 7 | $196 |
| SK Life Science, Inc. | 7 | $185 |
| Lundbeck LLC | 4 | $171 |
| Novartis | 3 | $129 |
| Bristol Myers Squibb | 8 | $117 |
| Amneal Pharmaceuticals LLC | 7 | $112 |
| Kyowa Kirin, Inc. | 1 | $98 |
| EMD Serono, Inc. | 6 | $86 |
| Pfizer | 4 | $74 |
| Johnson & Johnson | 4 | $52 |
| Neurocrine Biosciences, Inc. | 4 | $52 |
| Tanabe Pharma America, Inc. | 3 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| Neurelis, Inc. | 3 | $42 |
| Biohaven Pharmaceuticals, Inc. | 3 | $40 |
| Eisai Inc. | 2 | $36 |
| Acadia Pharmaceuticals Inc | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Argenx US, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
| Corium, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,756 in reported general payments places this provider in the 60th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 15 | $125,950 |
| QuliptaAtogepant | 93 | $108,635 |
| BriviactBrivaracetam | 19 | $25,560 |
| XcopriCenobamate | 16 | $23,869 |
| UbrelvyUbrogepant | 15 | $13,506 |
| XadagoSafinamide Mesylate | 12 | $13,501 |
| Ajovy SyringeFremanezumab-Vfrm | 12 | $9,558 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $8,393 |
| Lacosamide | 39 | $7,061 |
| HorizantGabapentin Enacarbil | 12 | $5,954 |
| Rasagiline Mesylate | 37 | $5,404 |
| Memantine Hcl | 104 | $5,128 |
| Carbamazepine ErCarbamazepine | 20 | $5,022 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 33 | $4,771 |
| RytaryCarbidopa/Levodopa | 12 | $4,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $1,469 | $122,142108 claims |
| UCB, Inc.Briviact | $369 | $25,56019 claims |
| SK Life Science, Inc.Xcopri | $185 | $23,86916 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $249 | $8,39311 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $21 | $5,95412 claims |
| Amneal Pharmaceuticals LLCRytary | $112 | $4,43812 claims |
| Upsher-smith Laboratories LLCTopiramate | $13 | $1,03562 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 521 neurology providers in New Jersey.
Other neurology in Mercerville
- Mary Ann PiconeTeaneck$2.8M
- Steven BromleyAudubon$1.7M
- David DuncanNeptune$1.5M
- Lana Zhovtis RyersonNeptune$1.3M
- Amos KatzEatontown$1.2M
- Fiona GuptaOradell$1.1M
- Andrew SylvesterBridgewater$1.1M
- Machteld HillenNewark$999K
- Matthew TremblayLivingston$812K
- Noah GilsonWest Long Branch$800K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.